Our subsidiary 4Moving Biotech, was presented at OARSI- World Congress on Osteoarthritis. It was an excellent opportunity to share our subsidiary’s latest progress and development.
Our subsidiary Co-founder/CMO Pr. Francis Berenbaum showcased two posters during the OARSI congress.
First poster at OA clinical trial symposium on March 16, 2023
Poster title: GLP1 analogues as a potential DMOAD: why, how, when?
The second Poster was a keynote presented during the OA research plenary session on March 17, 2023.
Poster title: Have We Been Driving in the Wrong Lane? Pivoting from Past Setbacks to Future Therapeutic Successes
